BioVeteria Launches LeukoSTAT®

BioVeteria Life Sciences, LLC (BioVeteria) announced they have partnered with IMULAN BioTherapeutics, LLC to distribute a new 60-count version of LeukoSTAT®. LeukoSTAT® contains a patented, orally active amino acid complex termed the Immune Selective Anti-Inflammatory Derivatives, or ImSAIDs®. The ImSAIDs® aid in modulating leukocyte related inflammatory conditions and have been studied in a variety of inflammatory models including pancreatitis, endotoxemia, asthma, anaphylaxis, and arthritis. BioVeteria has started programs to examine LeukoSTAT® for intestinal and oral health in cats and dogs where leukocyte (lymphocyte, plasmacyte, granulocyte) activity is considered a primary factor. Targeting leukocyte activation and transmigration is becoming a popular target for inflammatory intervention since leukocytes participate and coordinate all inflammatory events. The ImSAIDs® are a new class of naturally occurring immuno-nutritional complexes that help support a reduction in leukocyte over-activation. In a recent edition of the Journal of Inflammation ^[1], the immuno-pharmacology of the ImSAIDs® is reviewed in detail and discusses the novel immunological mechanisms which includes reduction in over-exuberant immune cell activation (leukocytes, granulocytes) and their production of reactive oxygen species. ^[1] Mathison et al.: Salivary gland derived peptides as a new class of anti-inflammatory agents: review of preclinical pharmacology of C-terminal peptides of SMR1 protein. Journal of Inflammation 2010 7:49 ; Hyperlink to Paper: http://www.journal-inflammation.com/content/7/1/49

More from

• Animus launches SkinBond Multi for enhanced wound care
• IVC Evidensia reports 82% cut in Farm antibiotic use and 20% carbon emissions reduction
• Vet professionals flock to sign up to transformative locum platform
• The ProSalus Foundation launches urgent appeal for UK vets to support Ukrainian colleagues
• Vetsure Named Business of the Year at 2025 SME National Business Awards